design
inhibitori
molecul
variou
viral
target
strategi
use
identifi
viral
vaccin
target
summar
viral
surfac
protein
strategi
use
target
protein
includ
viral
surfac
glycoprotein
viral
receptor
potenti
candid
antivir
vaccin
develop
strategi
use
target
includ
receptorbas
ligandbas
drug
design
receptorbas
drug
design
map
ligand
done
ligand
molecul
engin
assembl
littl
piec
stepwis
manner
within
bind
pocket
constraint
ligandbas
approach
ligand
specif
receptor
determin
use
biophys
simul
construct
chemic
librari
avail
structur
inform
expand
possibl
identifi
vaccin
candid
screen
map
epitop
use
bioinformat
tool
epivax
epimatrix
tan
et
al
de
groot
mois
target
viral
proteinsenzym
peptidomimet
drug
design
variou
viral
enzym
proteas
variou
techniqu
xray
crystallographi
nuclear
magnet
reson
nmr
comput
studi
also
enabl
success
design
antivir
drug
tsantrizo
wei
zhou
target
interact
mutat
cellbas
yeast
two
hybrid
variou
biophys
method
surfac
plasmonreson
isotherm
calorimetri
fluoresc
energi
reson
transfer
fret
base
differenti
scan
calorimetri
help
studi
essenti
interact
potenti
antivir
mutat
studi
protein
interfac
result
increas
decreas
bind
affin
one
viral
protein
protein
henc
impli
benefici
role
viral
life
cycl
brito
pinney
target
host
factor
variou
cellular
protein
signal
transduct
pathway
potenti
drug
target
antivir
molecul
host
factor
involv
viral
replic
target
prevent
hijack
host
system
viru
strategi
like
rapid
immunoaffin
purif
target
virushost
protein
follow
mass
spectrometri
identifi
associ
protein
impli
rowl
et
al
target
rnaprotein
interact
use
riboproteom
approach
profil
rnaprotein
interact
rna
coimmunoprecipit
help
identifi
protein
interact
viral
rna
salim
et
al
yeh
et
al
fig
intens
diffract
ray
detect
fed
comput
use
mathemat
equat
calcul
posit
everi
atom
crystal
molecul
result
threedimension
digit
imag
molecul
rhode
xray
crystallographi
help
reveal
detail
threedimension
structur
thousand
protein
mani
advanc
drug
discoveri
medicin
due
xray
crystallographi
identifi
drug
target
mani
diseas
macromolecular
crystallographi
power
techniqu
drug
discoveri
promin
role
find
drug
target
mani
diseas
major
challeng
today
exampl
hiv
proteas
structur
identifi
use
xray
crystallographi
klei
et
al
knowledg
structur
led
identif
variou
antivir
compound
interact
activ
site
enzym
munshi
et
al
similar
way
structur
mani
protein
virus
target
stop
viral
invas
comput
predict
help
threedimension
crystal
structur
target
viru
viral
protein
invit
structuresbas
drug
design
particular
target
viral
protein
drug
discoveri
xray
crystallographi
also
pave
way
make
drug
effect
molecular
detail
drug
target
site
reveal
atom
level
ad
atom
structur
potenti
viral
target
complex
drug
also
elucid
mechan
inhibit
drug
interact
molecular
level
make
work
munshi
et
al
anoth
power
biophys
techniqu
nmr
spectroscopi
give
inform
structur
also
dynam
viral
protein
complex
marion
nuclei
singl
atom
absorb
differ
radio
frequenc
accord
environ
protein
adsorpt
signal
may
perturb
adjac
nuclei
determin
distanc
nuclei
distanc
turn
use
determin
overal
structur
protein
nmr
success
techniqu
use
find
protein
interact
small
molecul
drug
inhibit
interact
bakail
ochsenbein
also
help
identifi
possibl
hit
pharmaceut
use
structur
gener
nmr
structur
analysi
indic
number
conform
protein
solut
use
design
small
antivir
molecul
target
protein
activ
site
recent
year
major
advanc
made
cryoelectron
microscopi
cryoem
techniqu
emerg
one
use
power
structur
biolog
techniqu
enabl
character
complex
biolog
system
cryoem
evolv
power
tool
structur
determin
macromolecular
complex
suitabl
crystallograph
nmr
studi
murata
wolf
structur
predict
protein
viru
model
done
use
electron
densiti
cryoem
map
henc
cryoem
reliabl
method
structur
determin
macromolecul
macromolecular
complex
drug
bound
viral
enzym
activ
site
neutral
antibodi
bound
viru
surfac
epitop
studi
use
cryoem
techniqu
ripol
et
al
avail
structur
knowledg
lead
ration
design
synthesi
potent
drug
molecul
vaccin
viral
diseas
drug
design
drug
discoveri
extrem
import
anim
human
health
care
comput
computerbas
approach
serv
import
role
structurebas
drug
design
structurebas
drug
design
util
threedimension
structur
protein
target
design
potenti
candid
drug
bind
select
high
affin
drug
target
anderson
comput
approach
util
variou
method
structureassist
design
drug
molecul
object
design
drug
base
avail
protein
invent
advanc
molecul
bind
tightli
drugabl
site
compet
natur
substrat
protein
moder
inhibit
function
viral
therapi
structurepick
drug
molecul
found
basi
protein
structur
effect
less
toxic
molecular
dock
method
use
spatial
shape
protein
activ
site
drug
expect
bind
select
suitabl
compound
potenti
ration
design
effect
antivir
drug
de
ruyck
et
al
protein
whose
crystal
difficult
perform
homolog
model
put
use
construct
model
given
protein
basi
relat
similar
known
structur
homolog
structur
howev
crystal
structur
protein
alreadi
known
knowledg
regard
activ
site
residu
involv
catalysi
becom
import
follow
comput
virtual
screen
compound
librari
small
molecul
small
molecul
select
dock
target
protein
molecular
dock
simul
predict
bind
orient
potenti
molecul
drug
candid
protein
target
predict
affin
activ
small
molecul
katsila
et
al
number
power
softwar
program
exampl
autodock
hex
gold
flexx
dock
glide
surflex
ligandfit
use
predict
dock
calcul
select
silico
potenti
drug
candid
test
vitro
antivir
effect
use
comput
comput
method
form
core
comput
drug
design
avail
protein
structur
highperform
comput
etc
enhanc
modern
day
drug
discoveri
process
comput
tool
offer
advantag
way
new
drug
candid
quick
cheap
variou
structurebas
approach
identifi
design
antivir
drug
anim
virus
discuss
tabl
introduct
foot
mouth
diseas
viru
fmdv
belong
picornavirida
famili
virus
caus
foot
mouth
diseas
fmd
clovenhoof
anim
fmdv
transmit
close
contact
anim
longdist
aerosol
spread
inanim
object
like
fodder
motor
vehicl
highli
contagi
cattl
pig
buffalo
goat
sheep
etc
affect
everi
part
world
livestock
kept
countri
still
affect
fmdv
affect
wild
domest
rumin
therefor
major
concern
trade
livestock
anim
product
caus
acut
prolong
asymptomat
persist
infect
fmdv
prolifer
rapidli
infect
speci
caus
vesicular
diseas
feet
mouth
seven
serotyp
includ
wide
rang
variant
defin
fmdv
fmdv
virion
consist
nucleic
acid
capsid
enclos
genom
positivestrand
rna
viru
genom
encod
singl
long
open
read
frame
orf
flank
untransl
region
utr
untransl
region
utr
viral
orf
upon
translat
process
give
rise
four
structur
protein
nonstructur
protein
nsp
cleavag
intermedi
forss
et
al
fmdv
take
host
control
repress
host
translat
machineri
innat
immun
respons
infect
like
mani
virus
cleav
cellular
protein
associ
signal
pathway
block
protein
secret
critic
role
nsp
noncod
element
fmdv
regul
biolog
process
like
virus
fmdv
viru
undergo
evolut
mutat
thu
one
hurdl
design
vaccin
within
serotyp
fmdv
incub
period
fmdv
usual
rang
day
symptom
includ
high
fever
day
blister
insid
mouth
lead
foami
saliva
blister
feet
swell
testicl
matur
male
declin
milk
product
cow
diseas
also
lead
myocard
inflamm
heart
muscl
death
newborn
anim
asymptomaticinfect
domest
anim
may
also
serv
carrier
except
pig
jamal
belsham
fmdv
seven
distinct
serotypeso
c
southern
african
territori
serotyp
discov
valle
carr
serotyp
c
discov
waldmann
trautwein
later
anoth
three
serotyp
identifi
sampl
south
africa
last
serotyp
identifi
sampl
collect
okara
punjab
pakistan
water
buffalo
longjam
et
al
fmdv
nm
spheric
shape
particl
fmdv
virion
symmetr
protein
shell
call
capsid
enclos
nucleic
acid
capsid
consist
copi
capsom
capsom
compos
four
structur
polypeptid
name
fmdv
genom
consist
singlestrand
positivesens
rna
kb
length
rna
encod
singl
long
orf
kb
viral
orf
flank
long
utr
short
utr
viral
genom
polya
tail
small
protein
around
residu
long
known
vpg
encod
region
viral
genom
coval
attach
end
genom
vpg
protein
releas
infect
cell
play
role
translat
initi
viral
orf
translat
polyprotein
around
kda
cleav
two
virusencod
proteas
name
leader
l
pro
pro
form
structur
nonstructur
protein
gener
orf
divid
four
area
due
differ
function
matur
polypeptid
region
arel
region
p
region
region
region
l
region
locat
end
capsid
encod
l
pro
p
region
encod
precursor
capsid
polypeptid
gener
capsid
cleav
viral
proteas
region
code
three
viral
region
code
four
viral
pro
pol
viral
proteas
act
rnadepend
rna
polymeras
rdrp
viral
nonstructur
protein
play
import
role
virusmedi
host
evas
longjam
et
al
first
fmdv
nsp
translat
l
pro
whose
region
lie
polyprotein
preced
capsid
precursor
protein
protein
two
altern
form
name
lab
pro
lb
pro
vitro
vivo
form
l
pro
papainlik
proteas
releas
polyprotein
via
cleavag
cterminu
nterminu
l
pro
major
virul
factor
requir
viral
replic
l
pro
cleav
host
translat
initi
factor
thu
repress
hostcel
translat
shut
host
capdepend
mrna
translat
l
pro
also
suppress
host
innat
immun
reaction
viral
infect
block
interferon
activ
fmdv
amino
acid
peptid
lack
proteas
motif
howev
characterist
ctermin
motif
glu
x
asnprogli
pro
cleav
precursor
pro
pro
cleavag
event
occur
polypeptid
synthesi
way
peptid
remain
connect
structur
protein
precursor
cleavag
proteolyt
event
modif
translat
machineri
peptid
help
releas
protein
allow
synthesi
downstream
protein
proceed
protein
viroporin
hydrophob
transmembran
low
molecular
weight
protein
fmdv
code
aa
peptid
slightli
longer
viroporin
contain
two
predict
put
transmembran
domain
locat
posit
aa
aa
transmembran
hydrophob
domain
interact
phospholipid
bilay
increas
membran
permeabl
facilit
releas
viral
particl
crucial
viral
pathogen
protein
amino
acid
long
protein
consist
amphipath
helix
ntermin
nsp
involv
mani
biolog
function
link
membran
target
protein
aa
peptid
conserv
fmdv
strain
code
region
nterminu
posit
encod
hydrophil
well
hydrophob
domain
capabl
bind
membran
fmdv
membran
bind
activ
base
hydrophob
motif
protein
known
vpg
coval
bound
terminu
genom
first
step
replic
picornaviru
genom
uridylyl
vpg
peptid
primer
genom
termin
featur
vpgu
pu
coval
link
allow
use
vpg
peptid
primer
synthes
viral
rna
pro
chymotrypsinlik
cystein
proteas
respons
cleavag
viral
polyprotein
pol
rdrp
synthes
posit
neg
strand
viral
rna
catalyt
compon
rna
replic
play
import
role
life
cycl
fmdv
pol
sequenc
highli
conserv
among
differ
serotyp
well
subtyp
fmdv
gao
et
al
vaccin
limit
spread
viru
epidem
fmdfree
countri
well
endem
region
thu
play
vital
role
fmd
control
recent
vaccin
typic
produc
inactiv
whole
viru
vaccin
quantiti
stabil
intact
viral
capsid
final
prepar
first
promis
novel
fmd
vaccin
licens
manufactur
use
unit
state
park
adenovirusvector
fmd
vaccin
caus
vivo
express
viral
capsid
vaccin
anim
anoth
promis
vaccin
compos
stabil
empti
fmdv
capsid
produc
vitro
baculoviru
express
system
cao
et
al
area
research
includ
enhanc
adjuv
vaccin
qualiti
control
procedur
vaccin
protect
immun
correl
variou
protein
fmdv
target
design
antivir
structuralbas
comput
approach
use
find
potent
inhibitor
molecul
fmdv
first
crystal
structur
fmdv
reduc
form
report
crystal
structur
fmdv
rdrp
polymeras
determin
ligandfre
complex
templateprim
rna
ferrerorta
et
al
fig
conserv
amino
acid
side
chain
bind
templateprim
complex
help
mediat
initi
rna
synthesi
crystal
structur
shed
light
import
inform
studi
viral
rna
replic
concept
design
antivir
compound
crystal
structur
fmdv
proteas
report
reveal
new
insight
structuralfunct
aspect
viral
replic
enzym
crystal
structur
fmdv
confirm
belong
famili
chymotrypsinlik
cystein
proteas
barrett
rawl
protein
compris
two
sixstrand
barrel
barrel
one
face
protein
lie
peptid
bind
cleft
activ
site
enzym
fmdv
proteas
crystal
structur
pave
way
structuralbas
drug
design
curri
et
al
fig
sever
inhibitor
molecul
crystal
structur
fmdv
identifi
target
novel
bind
pocket
could
use
futur
structurebas
drug
design
studi
durk
et
al
fig
knowledg
structur
viral
capsid
allow
engin
thermost
capsid
howev
capsid
stabil
effect
viral
vaccin
concern
molecular
dynam
md
base
strategi
evalu
mutat
design
increas
stabil
capsid
increas
noncoval
interact
develop
therefor
bound
rna
repres
stick
protein
repres
alpha
helix
beta
sheet
interact
catalyt
activ
site
residu
rna
also
shown
pdb
id
ferrerorta
et
al
design
md
protocol
allow
deriv
structuralbas
design
stabil
fmdv
virus
empti
capsid
allow
develop
stabl
vaccin
kotecha
et
al
crystal
structur
mutant
viral
polymeras
less
sensit
ribavirin
report
ferrerorta
et
al
fmdv
proteas
show
two
barrel
lie
protein
activ
site
activ
site
residu
includ
catalyt
triad
alpha
helic
beta
sheet
shown
pdb
id
curri
et
al
herpesvirus
hsv
doublestrand
ds
dna
virus
anim
belong
herpesvirida
famili
natur
host
rang
includ
mollusc
fish
amphibian
bird
reptil
mammal
includ
human
be
caus
mucocutan
lesion
insid
oral
caviti
well
genit
infect
human
nine
speci
herp
viru
take
human
primari
host
caus
diseas
rang
mild
lesion
seriou
malign
serolog
preval
percentag
higher
popul
develop
countri
develop
countri
mani
human
herp
viru
widespread
human
herp
viru
due
fact
viru
infect
asymptomat
mild
unnot
symptom
also
viru
capabl
establish
latent
recurr
infect
host
herp
viru
infect
seriou
concern
especi
danger
immunocompromis
patient
jiang
et
al
herp
virus
group
three
subfamili
alpha
beta
gamma
herpesviru
hsv
envelop
dna
viru
nm
diamet
linear
ds
dna
around
kbp
viru
icosadeltahedr
capsid
consist
capsom
larg
segment
contain
viral
protein
extern
trilaminar
lipid
envelop
constitut
least
glycoprotein
genom
compos
two
region
name
uniqu
long
region
ul
uniqu
short
region
us
link
coval
flank
three
segment
hsv
three
origin
replic
ori
one
copi
oril
two
copi
ori
vadlapudi
et
al
hsv
lytic
cycl
divid
three
step
viral
entri
viral
replic
viral
assembl
exit
viral
entri
depend
type
cell
initi
viral
glycoprotein
bind
hostcel
receptor
viral
envelop
either
fuse
plasma
membran
undergo
endocytosi
five
total
twelv
viral
envelop
protein
essenti
viral
infect
glycoprotein
c
gc
gb
gd
gh
gl
gb
act
homooligom
wherea
gh
gl
form
function
heterooligom
bind
gc
heparan
sulfat
initi
viru
contact
host
cell
postinfect
nucleu
host
rna
polymeras
ii
initi
viral
gene
express
earli
late
gene
hsv
dna
replic
via
sigma
rollingcircl
mechan
postdna
replic
gene
transcrib
form
viral
structur
compon
requir
capsid
assembl
transport
nucleu
via
nuclear
local
sequenc
procapsid
packag
along
viral
dna
form
matur
capsid
assembl
insid
cytoplasm
capsid
envelop
bud
golgi
compart
final
secret
infect
cell
herp
virus
abil
undergo
latenc
host
lifetim
latenc
viral
transcript
shut
except
kb
transcript
associ
latenc
thu
call
latenc
associ
transcript
unstabl
polyadenyl
primari
transcript
process
two
stabl
intron
extend
halfliv
reactiv
proper
stimuli
ultraviolet
stress
immunesuppress
virus
get
activ
enter
lytic
cycl
result
spread
variou
diseas
boehmer
nimonkar
number
antivir
molecul
target
present
nucleosid
analog
except
foscarnet
cidofovir
acyclovir
famciclovir
valaciclovir
use
treat
major
case
bacon
et
al
medic
foscarnet
valganciclovir
ganciclovir
cidofovir
activ
alpha
herpesvirus
recommend
certain
circumst
treatment
acyclovirresist
hsv
antivir
drug
treatment
hsv
infect
develop
past
year
howev
drugresist
hsv
isol
report
resist
acyclovir
etc
demand
need
highli
effect
low
toxic
drug
hsvresist
isol
whole
antivir
design
process
base
structur
find
hsv
jiang
et
al
virus
famili
herpesvirida
caus
innumer
human
diseas
year
avail
treatment
larg
ineffect
except
drug
treatment
herp
simplex
viru
hsv
infect
howev
dna
virus
famili
advanc
made
biochemistri
structur
biolog
enzym
viral
proteas
reveal
common
featur
exploit
develop
new
class
antiherpesviru
drug
herpesviru
proteas
identifi
uniqu
class
serin
proteas
serhishi
catalyt
triad
new
singl
domain
protein
fold
determin
xray
crystallographi
proteas
hsv
shown
dimer
uniqu
serin
proteas
requir
activ
hsv
proteas
known
fact
dimer
seriou
impact
function
analysi
inhibitor
discoveri
conserv
function
catalyt
properti
herpesviru
proteas
enzym
lead
common
consider
process
inhibitor
discoveri
crystal
structur
herpesviru
proteas
allow
direct
interpret
ligand
relationship
waxman
dark
fig
addit
screen
chemic
librari
provid
novel
structur
start
point
drug
develop
human
herpesviru
hhv
capsid
use
logphas
cultur
bodi
cavitybas
lymphoma
cell
induc
obtain
electroncryo
microscopi
comput
reconstruct
structur
capsid
reveal
capsid
shell
compos
penton
hexon
triplex
arrang
icosahedr
lattic
structur
similar
herp
simplex
viru
type
human
cytomegaloviru
prototyp
member
alpha
beta
herpesvirus
respect
wu
et
al
till
herpesvirus
second
lead
caus
human
viral
diseas
especi
danger
immunocompromis
individu
common
therapi
herp
viral
infect
use
nucleosid
analog
acyclovir
target
viral
dna
polymeras
essenti
viral
dna
replic
problem
class
drug
exhibit
narrow
antivir
spectrum
resist
agent
emerg
problem
need
hour
better
understand
herp
viru
replic
could
help
develop
safe
effect
broadspectrum
antiherpet
first
crystal
structur
herpesviru
polymeras
herp
simplex
viru
type
dna
polymeras
resolut
report
liu
et
al
fig
structur
similar
polymeras
polymeras
allow
construct
high
confid
model
replic
complex
rc
polymeras
acyclovir
dna
chain
termin
novel
inhibit
mechan
establish
repres
seri
nonnucleosid
viral
polymeras
inhibitor
bound
polymeras
activ
site
well
interact
noncoval
polymeras
dna
duplex
virus
need
cellentri
protein
call
fusogen
order
get
host
cell
known
herp
viru
fusogen
act
alon
need
complex
viral
cellentri
protein
complex
structur
determin
turn
protein
complex
fusogen
regul
fusogen
also
establish
certain
antibodi
interfer
complex
regul
fusogen
gave
clue
certain
antivir
design
target
interact
turn
prevent
viral
structur
herp
viru
proteas
solv
xray
crystallographi
catalyt
triad
locat
solvent
expos
surfac
protein
activ
site
catalyt
site
residu
shown
circl
pdb
id
waxman
dark
infect
mesri
et
al
nonnucleosid
inhibitor
hsv
dna
polymeras
target
site
less
import
bind
natur
nucleosid
nucleosid
inhibitor
use
crystal
structur
hsv
dna
polymeras
possibl
new
lead
molecul
base
apyron
analog
nonnucleosid
inhibitor
came
light
use
structurebas
model
approach
karampuri
et
al
differ
silico
approach
appli
virtual
screen
potenti
inhibitor
target
glycoprotein
complex
format
interfac
hsv
use
structurebas
virtual
screen
gb
glycoprotein
mani
potent
inhibitor
molecul
separ
target
activ
residu
involv
bind
activ
hussain
basha
naresh
kumar
natur
product
new
antivir
mechan
suggest
target
hsv
protein
like
dna
helicaseprimas
complex
fight
drug
resist
hsv
new
type
molecul
antihsv
agent
flavonoid
sugarcontain
compound
peptid
jiang
et
al
new
antivir
mechan
includ
lethal
mutagenesi
propos
novel
chemotherapeut
strategi
drug
resist
high
frequenc
mutat
viral
genom
lead
larg
danger
genet
mutat
caus
reduct
viral
infect
activ
therefor
lethal
mutagenesi
may
effect
weaken
capac
viru
drug
resist
one
nucleosid
analog
ribavirin
exhibit
broad
spectrum
antivir
activ
dna
rnabas
virus
structur
hsv
portalvertex
subnanomet
resolut
solv
cryoem
singleparticl
reconstruct
report
mcelwe
et
al
led
number
new
discoveri
includ
presenc
two
previous
unknown
portalassoci
structur
moreov
reconstruct
reveal
viral
dna
packag
within
capsid
lefthand
spool
arrang
concentr
shell
ad
data
also
shown
molecular
machin
play
critic
role
replic
cycl
import
famili
human
pathogen
target
use
design
antivir
coronavirus
belong
subfamili
coronavirina
famili
coronavoroda
coronavirus
envelop
virus
contain
singlestrand
positivesens
rna
genet
materi
rna
surround
nucleocapsid
helic
symmetri
genom
size
coronavirus
vari
kb
largest
rna
viru
mani
protein
contribut
overal
structur
coronavirus
name
spike
envelop
e
membran
nucleocapsid
n
coronaviru
mainli
infect
mammal
bird
brian
baric
human
infect
six
known
strain
coronavirus
mammal
bird
coronavirus
infect
upper
respiratori
gastrointestin
tract
human
coronavirus
caus
cold
fever
throat
congest
pneumonia
bronchiti
human
coronaviru
call
sever
acut
respiratori
syndrom
coronaviru
sarscov
caus
sever
acut
respiratori
syndrom
sar
caus
uniqu
pathogenesi
rang
lower
upper
respiratori
tract
infect
cheng
et
al
case
sar
coronaviru
defin
receptorbind
domain
mediat
attach
viru
cellular
receptor
angiotensinconvert
enzym
replic
coronaviru
occur
cytoplasm
upon
viral
entri
host
cell
uncoat
rna
genom
deposit
cytoplasm
rna
methyl
cap
polyadenyl
tail
allow
rna
attach
ribosom
translat
enzym
replicas
encod
viral
genom
rna
transcrib
new
copi
rna
proteas
nonstructur
protein
coronaviru
cov
cleav
nonstructur
protein
long
polyprotein
fehr
perlman
follow
type
human
coronavirus
human
coronaviru
human
coronaviru
sarscov
human
coronaviru
new
coronaviru
human
coronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
previous
known
novel
coronaviru
hcovemc
unfortun
effect
antivir
coronaviru
urgent
need
develop
new
strategi
prevent
control
coronaviru
infect
understand
biolog
replic
pathogenesi
virus
better
understand
function
cov
protein
viru
replic
transcript
mechan
may
lead
develop
pioneer
antivir
structur
function
properti
spike
protein
coronaviru
character
bosch
et
al
function
viral
spike
glycoprotein
mediat
entri
coronaviru
crystal
structur
sarcovm
pro
main
proteas
also
solv
xue
et
al
reveal
main
proteas
structur
form
homodim
three
domain
monom
antiparallel
structur
domain
ii
similar
coronaviru
proteas
form
chymotrypsinlik
fold
respons
catalyt
reaction
nativ
structur
coronaviru
pro
report
solv
xray
crystallographi
bacha
sarscov
main
proteas
pro
protein
requir
matur
sarscov
vital
life
cycl
thu
make
attract
target
structurebas
drug
design
antisar
drug
lu
et
al
crystal
structur
sarscovm
pro
inhibitor
also
report
yang
et
al
fig
structurebas
virtual
screen
chemic
databas
contain
compound
base
structur
sarscovm
pro
perform
activ
compound
select
virtual
screen
approach
also
confirm
bioassay
taken
templat
build
core
structur
analog
search
final
complex
structur
potent
inhibitor
sarscovm
pro
solv
xray
crystallographi
help
studi
sarscovm
pro
inhibit
mechan
compound
crystal
structur
felin
coronaviru
complex
solv
xray
crystallographi
report
xiao
mani
broad
spectrum
inhibitor
pro
enzym
coronaviru
identifi
base
crystal
structur
enzym
virtual
screen
method
berri
et
al
pro
coronaviru
prove
effect
drug
discoveri
target
even
term
achil
heel
coronavirus
cov
helicas
one
evolutionari
conserv
protein
nidovirus
henc
make
import
target
drug
develop
hao
et
al
first
fulllength
crystal
structur
merscov
helicas
report
cov
helicas
ntermin
cyshisrich
domain
ch
three
zinc
betabarrel
domain
ctermin
helicas
core
durai
et
al
find
help
provid
novel
structur
inform
essenti
structurebas
drug
design
cov
alphavirus
belong
togavirida
famili
virus
envelop
posit
sens
singlestrand
rna
virus
alphaviru
particl
nm
diamet
tend
spheric
although
slightli
pleomorph
nm
isometr
nucleocapsid
alphavirus
infect
variou
vertebr
like
human
rodent
bird
fish
well
invertebr
transmiss
speci
individu
occur
mainli
mosquito
henc
also
call
arthropodborn
alphavirus
divid
old
world
virus
new
world
virus
chikungunya
viru
chikv
onyongnyong
viru
sindbi
viru
sinv
old
world
alphavirus
caus
rash
polyarthralgia
chronic
arthriti
new
world
alphavirus
eastern
equin
enceph
viru
eeev
venezuelan
equin
enceph
viru
veev
mostli
associ
neurolog
diseas
cold
war
unit
state
biolog
weapon
program
soviet
biolog
weapon
program
research
weapon
veev
croddi
et
al
caus
moder
morbid
low
mortal
human
sever
morbid
mortal
anim
eeev
veev
caus
mortal
hors
respect
compar
mortal
human
zack
paessler
salmonid
alphaviru
sav
uniqu
group
virus
caus
pancrea
diseas
sever
infect
fish
big
problem
inhibitor
bind
activ
site
sarscov
mpro
activ
site
residu
involv
interact
constitut
shown
circl
pdb
id
yang
et
al
econom
import
due
high
mortal
rate
poor
growth
perform
recov
fish
sav
infect
caus
massiv
loss
biomass
commerci
fish
farm
also
herath
et
al
alphaviru
genom
almost
kb
length
exhibit
two
orfson
encod
nonstructur
polyprotein
anoth
encod
structur
polyprotein
form
result
cleavag
nonstructur
polyprotein
necessari
regulatori
function
transcript
translat
viral
mrna
host
two
nsp
precursor
produc
viral
rna
use
hostcel
translat
machineri
carboxyltermin
proteas
domain
cleav
precursor
polyprotein
junction
cleavag
occur
tran
ci
wherea
ci
junction
final
cleavag
junction
result
format
complet
matur
nsp
nsp
along
host
protein
form
posit
strand
rc
allow
rna
templat
synthes
positivesens
genom
subgenom
rna
structur
polyprotein
translat
five
structur
protein
capsid
c
major
envelop
glycoprotein
protein
shin
et
al
protein
mrna
cap
enzym
mtase
guanylyltransferas
gtase
activ
mediat
methyl
cap
function
viral
abu
bakar
ng
sinv
protein
requir
membran
associ
enzymat
function
gtase
activ
sinv
metalion
depend
wherea
metal
requir
mtase
enzymat
activ
tomar
et
al
protein
alphaviru
cap
enzym
potenti
drug
target
distinct
molecular
mechan
cap
viral
rna
convent
cap
mechan
host
catalyz
methyl
guanosin
triphosph
gtp
transfer
methyl
group
sadenosylmethionin
gtp
molecul
posit
help
mtase
follow
guanylyl
reaction
involv
format
coval
complex
guanylyltransferas
gtase
alphaviru
nonstructur
protein
possess
variou
enzymat
activ
ntermin
region
contain
helicas
domain
seven
signatur
motif
superfamili
helicas
function
rna
triphosphatas
perform
viral
rna
cap
reaction
also
function
nucleotid
triphosphatas
thu
facilit
rna
helicas
activ
ctermin
region
contain
papainlik
cystein
proteas
respons
process
viral
nonstructur
polyprotein
abu
bakar
ng
narwal
et
al
singh
et
al
crystal
structur
cystein
proteas
veev
report
free
state
first
report
inhibitor
bound
alphavir
proteas
structur
structur
identifi
activ
site
residu
studi
may
assist
discoveri
potenti
proteas
inhibitor
veev
hu
et
al
exact
role
alphaviru
protein
much
clear
rc
protein
ntermin
macro
domain
phosphatas
activ
nucleic
acid
bind
abil
alphaviru
uniqu
domain
ctermin
hypervari
domain
recent
shown
role
pathogen
abu
bakar
ng
polymeras
highli
conserv
protein
alphavirus
ident
amino
acid
core
rnadepend
rna
polymeras
rdrp
domain
ctermin
end
rna
synthet
properti
viral
rc
tatas
activ
suggest
novel
function
alphaviru
rdrp
mainten
repair
poli
tail
element
requir
replic
viral
genom
tomar
et
al
last
decad
asia
europ
america
alphavirus
reemerg
focus
need
select
inhibitor
present
antivir
treatment
avail
viral
target
within
alphaviru
rc
includ
variou
molecular
determin
structur
function
analysi
target
make
structurebas
drug
design
develop
antivir
alphavirus
possibl
interact
identifi
chikv
mani
interact
shown
similarli
sinv
semliki
forest
viru
sfv
abu
bakar
ng
recruit
nsp
discuss
literatur
crucial
sfv
replic
membran
associ
lampio
et
al
interact
nsp
import
attract
target
drug
develop
inhibit
anchor
spherul
occur
affin
cell
membran
perturb
inhibit
recruit
nsp
thu
prevent
initi
rc
format
protein
viral
replic
host
evas
strategi
target
viral
inhibit
rna
helicas
rna
triphosphatas
nucleosid
triphosphatas
autoproteas
activ
import
cofactor
matur
viral
rc
kapp
proteas
good
drug
target
mani
virus
target
way
human
immunodefici
viru
hiv
hepat
c
viru
led
develop
mani
fdaapprov
inhibitor
lenz
et
al
weber
agniswami
virusspecif
rna
polymeras
good
target
inhibit
viral
dna
duplic
surviv
silico
drug
design
crystal
structur
proteas
great
interest
proteas
domain
crystal
structur
veev
chikv
sinv
also
present
protein
data
bank
pdb
entri
respect
crystal
structur
proteas
chikv
submit
pdb
id
use
crystal
structur
variou
peptidomimet
inhibitor
design
pro
dhindwal
et
al
fretbas
proteas
assay
use
analyz
proteolyt
activ
chikv
proteas
proteas
assay
use
assess
inhibitori
activ
peptidomimet
compound
identifi
conclud
two
peptidomimet
compound
pepi
mmsinc
databas
id
pepii
mmsinc
databas
id
inhibit
chikv
proteas
activ
potenti
antivir
drug
find
potenti
inhibitor
chikv
proteas
homolog
model
computeraid
drug
design
strategi
implement
first
time
bassetto
et
al
potenti
inhibitor
base
structur
studi
molecular
simul
report
nguyen
et
al
singh
et
al
lopinavir
nelfinavir
potent
hiv
proteas
inhibitor
fdaapprov
inhibitor
chikv
number
highli
select
chikv
veev
cap
enzym
inhibitor
report
recent
interrupt
activ
delang
et
al
gigant
et
al
gigant
et
al
nucleosid
analog
also
shown
effect
sever
alphavirus
ribavirin
inhibit
chikv
sfv
genom
replic
deplet
gtp
pool
briolant
et
al
moreov
inhibit
rdrp
ribavirin
interact
residu
increas
replic
fidel
coffey
et
al
nhc
anoth
nucleosid
analog
potent
inhibitor
veev
serv
substitut
ribavirin
develop
nhc
resist
mutant
favipiravir
anoth
inhibitor
potent
antivir
chikv
infect
inhibit
interact
residu
compounda
could
potenti
inhibit
rdrp
ribonucleotid
select
function
target
wada
et
al
howev
believ
chemic
modif
compounda
may
start
point
reduc
toxic
structur
capsid
protein
aura
viru
complex
piperazin
report
piperazin
small
heterocycl
molecul
dock
studi
shown
bind
hydrophob
pocket
chikv
capsid
protein
effect
antialphavir
drug
aggarw
et
al
crystal
structur
chikv
capsid
proteas
domain
determin
found
small
molecul
mandel
acid
ethyl
target
capsid
hydrophob
pocket
bind
conserv
hydrophob
pocket
cp
sharma
et
al
may
serv
basi
develop
antivir
chikv
infect
crystal
structur
determin
reveal
protein
consist
two
subdomain
ntermin
proteas
subdomain
ctermin
methyltransferas
subdomain
addit
structur
insight
reveal
access
activ
site
substrat
bind
cleft
block
flexibl
interdomain
loop
chikv
may
serv
benefici
structurebas
drug
design
optim
chikv
proteas
inhibitor
recent
highthroughput
elisabas
assay
develop
screen
inhibitor
dival
metaliondepend
alphaviru
cap
enzym
variou
inhibitor
sinefungin
aurintricarboxyl
acid
ribavirin
assess
inhibitori
effect
report
addit
proteasebas
cellfre
highthroughput
screen
assay
evalu
inhibitor
emerg
chikv
develop
saha
et
al
success
method
identifi
antiproteas
molecul
togeth
highthroughput
screen
assay
lead
develop
industri
level
largescal
screen
platform
identif
proteas
inhibitor
emerg
reemerg
virus
paramyxovirida
famili
divid
two
subfamili
paramyxovirinar
pneumovirina
paramyxovirina
subfamili
five
genera
name
respiroviru
rubulaviru
avulaviru
morbilliviru
henipaviru
subfamili
compris
variou
virus
like
measl
mump
newcastl
diseas
parainfluenza
hendra
nipah
virus
niv
second
subfamili
pneumovirina
compris
two
genera
pneumoviru
metapneumoviru
subfamili
also
includ
new
human
anim
pathogen
human
bovin
respiratori
syncyti
virus
specif
affect
bovin
caprin
ovin
speci
human
avian
metapneumovirus
paramyxovirus
includ
major
diseas
caus
pathogen
caus
signific
health
hazard
aguilar
lee
envelop
rna
infect
host
help
two
surfac
glycoprotein
fuse
lipid
membran
hostcel
plasma
membran
virus
attach
fusion
f
protein
membran
fusion
probabl
due
receptorinduc
conform
chang
within
attach
protein
lead
activ
fold
fusion
protein
plattet
plemper
paramyxovirus
main
caus
respiratori
diseas
children
one
two
viral
surfac
glycoprotein
hemagglutininneuraminidas
hn
variou
function
addit
major
surfac
antigen
induc
neutral
antibodi
crystal
structur
multifunct
newcastl
diseas
viru
paramyxoviru
hn
alon
complex
inhibitor
report
fig
structur
provid
basi
structurebas
design
inhibitor
rang
paramyxovirusinduc
diseas
crennel
et
al
crystal
structur
secret
uncleav
ectodomain
paramyxoviru
present
yin
et
al
combin
xray
crystallographi
cryoelectron
tomographi
done
show
structur
matrix
protein
newcastl
diseas
viru
paramyxoviru
structur
sequenc
conserv
impli
paramyxoviru
matrix
protein
function
similarli
habchi
longhi
establish
favipiravir
may
serv
antivir
virus
hendra
viru
hev
niv
batborn
paramyxovirus
experiment
find
anim
demonstr
human
monoclon
antibodi
target
viral
g
glycoprotein
effect
postexposur
treatment
hendra
niv
infect
also
subunit
vaccin
base
g
glycoprotein
hev
afford
protect
hendra
niv
vaccin
develop
use
hors
australia
first
vaccin
biosafeti
agent
licens
commerci
deploy
hev
one
member
henipaviru
genu
paramyxovirus
design
organ
high
mortal
rate
niv
hev
human
paramyxoviru
cell
entri
mediat
fusion
protein
f
respons
bind
host
receptor
attach
protein
posttransl
process
fusion
peptid
f
releas
upon
receptorinduc
trigger
insert
hostcel
membran
f
undergo
dramat
refold
prefus
postfus
conform
bring
host
viral
membran
togeth
allow
entri
viral
rna
crystal
structur
prefus
form
hev
f
ectodomain
report
structur
show
great
similar
structur
prefus
parainfluenzaviru
fusion
protein
wong
et
al
first
success
treatment
henipaviru
infect
vivo
smallmolecul
drug
suggest
favipiravir
evalu
antivir
treatment
option
henipaviru
infect
daw
et
al
inhibitor
bind
pocket
surfac
neuraminidas
activ
site
activ
site
residu
protein
involv
interact
shown
circl
surfac
protein
pdb
id
crennel
et
al
avian
influenza
viru
belong
famili
orthomyxovirida
neg
sens
singlestrand
virus
classifi
three
type
b
c
base
antigen
differ
nucleoprotein
np
matrix
protein
influenza
major
pathogen
caus
epidem
influenza
influenza
genom
compos
eight
rna
segment
five
segment
code
one
protein
three
code
two
protein
protein
hemagglutinin
ha
na
matrix
protein
proton
channel
np
nonstructur
protein
nuclear
export
protein
nep
also
known
polymeras
acid
protein
pa
polymeras
basic
protein
protein
name
express
second
read
frame
gene
pa
form
rna
polymeras
surfac
glycoprotein
ha
na
provid
distinct
antigen
properti
influenza
viru
influenza
virus
organ
accord
ha
na
subtyp
du
et
al
sixteen
ha
subtyp
nine
na
subtyp
identifi
subtyp
bird
flu
swine
flu
virus
indic
crystal
structur
avian
hemagglutinin
report
crystal
structur
effector
domain
avian
influenza
viru
report
hale
et
al
crystal
structur
avian
influenza
polymeras
report
fig
unbolt
mani
possibl
target
viral
protein
design
new
antiinfluenza
therapeut
yuan
et
al
three
inhibitor
protein
na
approv
fda
name
zanamivir
relenza
glaxo
smith
kline
oseltamivir
tamiflu
roch
peramivir
rapivab
biocryst
zanamivir
first
approv
inhibitor
among
shen
et
al
structurebas
drug
discoveri
studi
done
target
interact
mani
potent
antiinfluenza
drug
report
help
silico
simul
studi
watanab
et
al
flavivirida
famili
consist
three
genera
includeflaviviru
genu
type
speci
yellow
fever
viru
largest
genu
hepaciviru
type
speci
hepat
c
viru
pestiviru
type
speci
bovin
viru
diarrhea
pestiviru
belong
famili
flavivirida
arthropodborn
mainli
infect
mammal
caus
diseas
like
hemorrhag
syndrom
abort
fatal
mucos
diseas
singlestrand
virus
positivesens
rna
genom
around
kb
long
polya
tail
end
genom
henc
virus
posttranscript
modif
simpl
rna
genom
genom
contain
rna
encod
structur
nsp
envelop
virus
icosahedrallik
particl
linear
genom
arrang
kumar
et
al
entri
hostcel
mediat
clathrinco
endocytosi
achiev
attach
viral
envelop
protein
e
host
receptor
vaccin
pestivirus
correct
vaccin
strain
given
depend
herd
locat
endem
strain
region
vaccin
must
given
regularli
maintain
immun
variou
speci
genu
pestivirusbord
diseas
viru
bovin
viral
diarrhea
viru
bvdv
classic
swine
fever
viru
etc
kumar
et
al
crystal
structur
rdrp
bvdv
report
pdb
id
structur
explain
mani
possibl
inhibitor
molecul
could
bind
shed
light
variou
inhibitor
bind
site
protein
lead
opportun
design
mani
structurebas
inhibitor
molecul
choi
et
al
fig
pol
consist
four
polypeptid
chain
contain
alpha
helic
betasheet
presenc
magnesium
ion
sphere
form
mg
ion
coordin
acid
residu
circl
amino
acid
except
conserv
influenza
viru
b
c
pdb
id
yuan
et
al
crystal
structur
bovin
viral
diarrhea
viru
envelop
glycoprotein
report
pdb
id
el
omari
et
al
basi
crystal
structur
bvdv
protein
smallmolecul
highthroughput
dock
perform
identifi
molecul
like
bind
envelop
protein
bvdv
sever
structur
differ
compound
purchas
well
synthes
assay
antivir
activ
bvdv
possibl
bind
determin
character
md
simul
common
pattern
interact
observ
activ
molecul
amino
acid
residu
bind
site
find
believ
offer
better
understand
interact
bvdv
inhibitor
well
benefit
discoveri
novel
potent
bvdv
antivir
el
omari
et
al
crystal
structur
helicas
pestiviru
report
pdb
id
tortorici
et
al
closedconform
crystal
structur
fulllength
pestiviru
proteas
cofactor
segment
establish
pdb
id
zheng
et
al
fig
alpha
helic
betasheet
shown
activ
site
residu
protein
involv
catalysi
circl
pdb
id
choi
et
al
chapter
variou
viral
protein
necessari
surviv
viru
insid
host
discuss
viral
polymeras
viral
helicas
proteas
etc
approach
use
predict
structur
necessari
protein
elabor
variou
drug
molecul
antivir
design
basi
structur
protein
highlight
detail
avail
inhibitor
potenti
antivir
candid
disclos
vaccin
statu
anim
virus
discuss
improv
need
novel
structurebas
drug
clinic
test
emphas
protein
structurebas
drug
design
contribut
drug
discoveri
process
sinc
earli
structur
knowledg
interact
drug
target
protein
appli
mainli
predict
potenc
chang
chemic
modifi
lead
compound
help
inform
addit
aspect
drug
discoveri
process
becom
predict
select
compound
homolog
ortholog
protein
predict
provid
new
possibl
design
select
compound
predict
suitabl
anim
model
pharmacodynam
studi
antivir
display
varieti
mechan
action
antivir
may
enhanc
anim
immun
system
block
specif
enzym
particular
step
viral
replic
cycl
virus
oblig
intracellular
parasit
use
host
cellular
machineri
surviv
multipli
essenti
antivir
harm
host
howev
major
concern
virus
continu
develop
new
antivir
resist
strain
due
high
mutat
rate
demand
mandatori
search
develop
new
antivir
compound
help
structurebas
drug
design
progress
preclin
drug
discoveri
deficit
inform
identifi
hit
mani
criteria
must
fulfil
side
side
convert
hit
preclin
candid
real
chanc
becom
drug
gap
bridg
investig
understand
interact
ligand
receptor
accur
calcul
free
energi
bind
still
elus
better
knowledg
help
find
good
drug
candid
combat
diseas
caus
anim
virus
